Rezo Therapeutics, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2022 | $68 M | No. 1 | $50 to $250 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Rezo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2025).
SEC Form D · Aug 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2025
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Rezo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Derek Hicks | Executive officer | Aug 2025 |
| Jennifer Chang | Executive officer | Aug 2025 |
| Nevan Krogan | Executive officer | Aug 2025 |
| Nadir Mahmood | Executive officer | Dec 2023 |
| Sourav Bandyopadhyay | Executive officer | Dec 2022 |
| Derek Hicks | Director | Aug 2025 |
| George Scangos | Director | Aug 2025 |
| Nevan Krogan | Director | Aug 2025 |
| Norbert Bischofberger | Director | Aug 2025 |
| Simeon George | Director | Aug 2025 |
| Tiba Aynechi | Director | Aug 2025 |
| Vineeta Agarwala | Director | Aug 2025 |
| Nadir Mahmood | Director | Dec 2023 |
| Nadir Mahmood | Promoter | Dec 2023 |
| Nevan Krogan | Promoter | Dec 2022 |
| Sourav Bandyopadhyay | Promoter | Dec 2022 |